Literature DB >> 16611098

Introduction: hereditary hemorrhagic telangiectasia as a rare disease.

Erica Daina1, Francesco D'Ovidio, Carlo Sabbà.   

Abstract

A disease is considered rare in the United States when it affects one individual per 1, 250 and one individual per 2,000 in Europe. Most rare diseases (RD) are of genetic origin; their rarity involves a difficult and/or late diagnosis. The greatest barrier to prevention, diagnosis and treatment of RD is inadequate knowledge. Hereditary haemorrhagic telangiectasia (HHT) is a "rare" genetic disorder that is becoming more commonly recognised. Recent evidence indicates that it is more frequent (1-2/10,000) than previously estimated. We suppose that the frequent misdiagnosis and the different genetic penetrance have led to an underestimation of real prevalence. In fact, progress in scientific knowledge and improvement in diagnostic and therapeutic technologies has unmasked conditions which were not fully known previously, determining a fictitious decrease in disease frequency.

Entities:  

Mesh:

Year:  2006        PMID: 16611098     DOI: 10.2174/138161206776361264

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  3 in total

Review 1.  Endoglin in liver fibrogenesis: Bridging basic science and clinical practice.

Authors:  Steffen K Meurer; Muhammad Alsamman; David Scholten; Ralf Weiskirchen
Journal:  World J Biol Chem       Date:  2014-05-26

2.  Interventional treatment of pulmonary arteriovenous malformations.

Authors:  Poul Erik Andersen; Anette Drøhse Kjeldsen
Journal:  World J Radiol       Date:  2010-09-28

Review 3.  An update on the ophthalmic features in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber syndrome).

Authors:  Solmaz Abdolrahimzadeh; Martina Formisano; Carla Marani; Siavash Rahimi
Journal:  Int Ophthalmol       Date:  2022-01-16       Impact factor: 2.029

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.